British Space Startup Launches Long-Lived Lab In Orbit

Place of residence the next frontier in longevity research.

British inventors have just launched a self-driving drug test in orbit, hoping that zero-gravity data can shed light on a group of proteins that cause diseases that are hard to study on Earth. But first they have to watch their autonomous laboratory work in space.

The Mass Balance spacecraft, which contains chemicals, sensors and control elements to make the chemicals work, was launched on a SpaceX transporter on Tuesday morning. Housed in a 10 centimeter (4 inch) dish built by the Austrian company Tumbleweed, the experiment will orbit the Earth for several months, testing itself and reviewing data on how living cells grow, react, and function under weak gravity.

It is the first test of a system that the company hopes can produce high-quality data not available on Earth, where gravity causes effects such as movement, where heat flows, and sediment, where heavy objects sink, to collect data.

“When you remove gravity, a lot of weird and wonderful things happen, some of which are very important in life science and medicine,” Mass Balance co-founder and CEO Toby Call says in an interview. “It sounds silly these days, but the goal is to make the space more boring, reliable and a place to explore.”

The research facility could be important for modeling disordered proteins, they say, that cause age-related diseases including Alzheimer’s, Parkinson’s, and other cancers.

On Earth, these proteins are constantly changing, which makes them difficult to map. This creates a gap between life science studies like Google’s AlphaFold, which makes it difficult for them to predict how misfolded proteins will behave – and respond to drugs.

But in space, scientists believe it other proteins that drive disease may be easier to study and analyze. Call for plans to generate data by measuring disordered proteins under low gravity and use it to train an AI model adapter that fills in the gaps – with the model, data permission, and data management costs of his company.

Currently, the company is only testing its operating system and data capture. Tuesday’s mission will take an industrial biocatalyst into space, which will break down certain chemicals. The platform will monitor the process using light to ensure that the treatment is done as planned.

A number of other laboratories are trying to develop circular laboratories. In May, the British company BioOrbit launched a test unit for high-growth, stable crystals that can be turned into cancer drugs, while America’s Varda Space Industries is also working on developing drugs under microgravity. Unlike the two companies, Mass Balance is not trying to bring its system back to Earth, which would avoid some of the major engineering challenges of ensuring it can withstand the extreme heat and stress of satellites as they reenter Earth’s atmosphere.

“Microgravity is a new tool that is used sparingly,” Call says.